Expertise in
10
conditions

Dr. Karen L. Tedesco

Hematology Oncology | Oncology | Hematology
New York Oncology Hematology PC
1700 Riverfront Ctr, 
Amsterdam, NY 
Expertise in
10
conditions
New York Oncology Hematology PC
1700 Riverfront Ctr, 
Amsterdam, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karen Tedesco is a Hematologist Oncology specialist and an Oncologist in Amsterdam, New York. Dr. Tedesco is highly rated in 10 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Multiple Myeloma.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Samaritan Hospital Of Troy, New York
Albany Medical Center Hospital
Nathan Littauer Hospital
St Mary's Healthcare
St Peter's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

NEW YORK ONCOLOGY HEMATOLOGY PC
1700 Riverfront Ctr, Amsterdam, NY 12010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Breast Cancer Index (BCI) Registry
Breast Cancer Index (BCI) Registry
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Diagnostic test
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 8 Less Clinical Trials

4 Total Publications

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Journal: NPJ breast cancer
Published: January 14, 2021
Similar Doctors
Expertise in
57
conditions
Dr. Sultana Razia
Hematology Oncology | Hematology | Oncology
Expertise in
57
conditions
Dr. Sultana Razia
Hematology Oncology | Hematology | Oncology

Slocum Dickson Medical Group PLLC

1729 Burrstone Rd, 
New Hartford, NY 
 (56.0 mi)
315-798-1500
Experience:
43+ years
Languages Spoken:
English
Offers Telehealth

Sultana Razia is a Hematologist Oncology specialist and a Hematologist in New Hartford, New York. Dr. Razia has been practicing medicine for over 43 years is highly rated in 57 conditions, according to our data. Her top areas of expertise are Subacute Combined Degeneration, Endometrial Cancer, Childhood Iron Deficiency Anemia, Salpingo-Oophorectomy, and Bone Marrow Aspiration.

Expertise in
40
conditions
Dr. Joseph J. Dudek
Hematology Oncology | Hematology | Oncology
Expertise in
40
conditions
Dr. Joseph J. Dudek
Hematology Oncology | Hematology | Oncology

New York Oncology Hematology PC

400 Patroon Creek Blvd, Suite 1, 
Albany, NY 
 (26.3 mi)
518-489-0444
Languages Spoken:
English
See accepted insurances

Joseph Dudek is a Hematologist Oncology specialist and a Hematologist in Albany, New York. Dr. Dudek is highly rated in 40 conditions, according to our data. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Thrombocytopenia, and Multiple Myeloma.

Expertise in
36
conditions
Dr. Manzurul A. Sikder
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Manzurul A. Sikder
Hematology Oncology | Hematology | Oncology

Slocum Dickson Medical Group PLLC

1729 Burrstone Rd, 
New Hartford, NY 
 (56.0 mi)
315-798-1500
Languages Spoken:
English
Offers Telehealth

Manzurul Sikder is a Hematologist Oncology specialist and a Hematologist in New Hartford, New York. Dr. Sikder is highly rated in 36 conditions, according to our data. His top areas of expertise are Vitamin B12 Deficiency Anemia, Folate Deficiency, Multiple Carboxylase Deficiency, Subacute Combined Degeneration, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tedesco's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 77 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile